EA202090602A1 - MPGES-1 INHIBITOR FOR TREATMENT OF OSTEOARTHRITIS PAIN - Google Patents

MPGES-1 INHIBITOR FOR TREATMENT OF OSTEOARTHRITIS PAIN

Info

Publication number
EA202090602A1
EA202090602A1 EA202090602A EA202090602A EA202090602A1 EA 202090602 A1 EA202090602 A1 EA 202090602A1 EA 202090602 A EA202090602 A EA 202090602A EA 202090602 A EA202090602 A EA 202090602A EA 202090602 A1 EA202090602 A1 EA 202090602A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mpges
inhibitor
osteoarthritis pain
treatment
subject
Prior art date
Application number
EA202090602A
Other languages
Russian (ru)
Inventor
Моника Тандон
Сумит Сант
Неелима Кхаираткар-Джоши
Гириш Гуди
Вину Си Эй Менон
Рави Таллури
Original Assignee
Икнос Сайенсис С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Икнос Сайенсис С.А. filed Critical Икнос Сайенсис С.А.
Priority claimed from PCT/IB2018/057244 external-priority patent/WO2019058295A1/en
Publication of EA202090602A1 publication Critical patent/EA202090602A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)

Abstract

Изобретение относится к ингибитору микросомальной простагландин-E-синтазы-1 (mPGES-1) для лечения остеоартритной боли у субъекта. Например, данное изобретение относится к способу лечения умеренной остеоартритной боли у субъекта, нуждающегося в этом, путем перорального введения субъекту замещенного соединения триазолона в качестве ингибитора mPGES-1. Данное изобретение также относится к фармацевтическим композициям, содержащим ингибитор mPGES-1, и к способам приготовления таких фармацевтических композиций.The invention relates to an inhibitor of microsomal prostaglandin-E-synthase-1 (mPGES-1) for the treatment of osteoarthritis pain in a subject. For example, this invention relates to a method for treating moderate osteoarthritis pain in a subject in need thereof by orally administering to the subject a substituted triazolone compound as an inhibitor of mPGES-1. The invention also relates to pharmaceutical compositions comprising an mPGES-1 inhibitor, and to methods for preparing such pharmaceutical compositions.

EA202090602A 2017-11-27 2018-09-20 MPGES-1 INHIBITOR FOR TREATMENT OF OSTEOARTHRITIS PAIN EA202090602A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721042452 2017-11-27
PCT/IB2018/057244 WO2019058295A1 (en) 2017-09-20 2018-09-20 Mpges-1 inhibitor for the treatment of osteoarthritis pain

Publications (1)

Publication Number Publication Date
EA202090602A1 true EA202090602A1 (en) 2020-06-18

Family

ID=71138823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090602A EA202090602A1 (en) 2017-11-27 2018-09-20 MPGES-1 INHIBITOR FOR TREATMENT OF OSTEOARTHRITIS PAIN

Country Status (1)

Country Link
EA (1) EA202090602A1 (en)

Similar Documents

Publication Publication Date Title
PH12021551065A1 (en) Fused ring compounds
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201891494A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201890161A1 (en) THERAPEUTIC COMPOSITIONS, COMBINATIONS AND APPLICATION METHODS
EA201990043A1 (en) ANTIBACTERIAL CONNECTIONS
EA201790492A1 (en) CONNECTIONS THAT INHIBIT McL-1 PROTEIN
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
EA201792529A1 (en) Thyrosine Kinase Inhibitors
EA201992128A1 (en) JAK CONDENSED IMIDAZOPIPERIDINE INHIBITORS
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201990044A1 (en) HETEROCYCLIC COMPOUNDS AS ANTIBACTERIAL MEANS
EA201691590A1 (en) BENZIMIDAZOL-2-AMINES AS MIDHI INHIBITORS
EA202090688A1 (en) BIS-AMIDE CONNECTIONS ACTIVATING SARCOMER AND VARIANTS OF THEIR APPLICATION
CY1125150T1 (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
EA201890449A1 (en) FUMAGILLINUM HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
EA201891342A1 (en) Isoindole compounds
EA202090414A1 (en) COMPOUNDS AND THEIR APPLICATION
EA201990678A1 (en) Heteroarylcarboxamide Compounds as Ripk2 Inhibitors
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
EA201792425A1 (en) TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS PHOSPHODYSTERASE INHIBITORS
EA201791432A1 (en) COMPOSITIONS ON THE BASIS OF MONOMETHYLATE PREPARATION
EA201890419A1 (en) SELECTED AMID OF γ-HYDROXYMIC ACID AND ITS APPLICATION IN THE TREATMENT OF ALCOHOL ACCEPTANCE
EA202092691A1 (en) PAIN RELIEF COMPOSITIONS, COMPOSITIONS AND METHODS FOR THEIR APPLICATION